Harvard Pilgrim now covers the medication Udenyca for members of our commercial plans. Udenyca was approved by the FDA in November as a biosimilar to Neulasta for the treatment of patients at risk for febrile neutropenia-related infection. As with Neulasta, the use of Udenyca (Q5111) requires prior authorization.
You can find the complete list of covered indications and coverage criteria on Harvard Pilgrim’s updated Neulasta and Udenyca prior authorization policy.
To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882). For more information, please refer to Harvard Pilgrim’s Neulasta and Udenyca Medical Review Policy and prior authorization request form.